- Molecular NameAmikacin
- Synonymamikacin; Amikacin Base; Amikacin Dihydrate; Amikacin Sulfate; Amikacina [INN-Spanish]; Amikacine [INN-French]; Amikacinum [INN-Latin]; ANTIBIOTIC BB-K8; BB-K8
- Weight585.608
- Drugbank_IDDB00479
- ACS_NO37517-28-5
- Show 2D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)-9.49
- pkaN/A
- LogD (pH=7, predicted)-15.05
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)0.23
- LogSw (predicted, AB/LogsW2.0)4944.55
- Sw (mg/ml) (predicted, ACD/Labs)1000.0
- No.of HBond Donors17
- No.of HBond Acceptors18
- No.of Rotatable Bonds10
- TPSA331.94
- StatusFDA approved
- AdministrationIntramuscular, intravenous
- PharmacologyAn aminoglycoside antibiotic used to treat different types of bacterial infections. Amikacin works by binding to the bacterial 30S ribosomal subunit, causing misreading of mRNA and leaving the bacterium unable to synthesize proteins vital to its growth.
- Absorption_value0.0
- Absorption (description)Poorly absorbed after oral administration but rapidly absorbed after intramuscular injection.
- Caco_2N/A
- Bioavailability0.0
- Protein binding4.0
- Volume of distribution (VD)0.27 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmN/A
- Half life2.3 h
- ExcretionAbout 90% of a dose is excreted in the urine unchanged in 24 h.
- Urinary Excretion98
- Clerance1.3 mL/min/kg.
- ToxicityToxic effects may be produced at serum concentrations of 30 mg/L or more or, during chronic treatment, if the trough serum concentration exceeds 10 mg/L. The following postmortem tissue concentrations were reported in a patient who died 5 days after discontinuation of amikacin treatment: serum 2.2 mg/L, heart 20 μg/g, kidney 794 μg/g, liver 30 μg/g, lungs 48 μg/g, muscle 11 μg/g. [M. A. French et al.,Antimicrob. Agents Chemother.,1981, 19, 147–152].
- LD50 (rat)N/A
- LD50 (mouse)N/A